US cites Taro's Canadian facility for GMP violations
This article was originally published in Scrip
Executive Summary
The US FDAwill not approve drug applications referencing Taro Pharmaceutical Industries' finished drug products facility in Ontario, Canada, until good manufacturing practice violations have been corrected.